* Aceragen Inc ACGN.OQ ACGN.O is expected to show no
change in
quarterly revenue when it reports results on June 9
(estimated).
*
* Refinitiv's mean analyst estimate for Aceragen Inc is for
a
loss of $2.12 per share.
* The one available analyst rating on the shares is "buy".
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "Buy".
* Wall Street's median 12-month price target for Aceragen
Inc is
$17, above its last closing price of $1.62.
This summary was machine generated June 9 at 20:32 GMT. All
figures in US dollars unless otherwise stated